Fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is based in San Francisco, California.
FGEN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Fibrogen Inc. To summarize, we found that Fibrogen Inc ranked in the 4th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for FGEN, they are:
The company has produced more trailing twelve month cash flow than only 17.69% of its sector Healthcare.
The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately merely 5.6% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Fibrogen Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -116.26. This coverage rate is greater than that of merely 1.81% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as FGEN, try ATRS, IVC, PHG, SSKN, and DRRX.
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDA...
NEW YORK , Sept. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FGEN, BYND, LLY, BAC, and TSLA. Click a link below then choose between in-depth options trade idea report or a stock score report. Full story available on Benzinga.com